Morgan Stanley Reata Pharmaceuticals Inc Transaction History

Morgan Stanley

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$79.22 - $105.37 $6.35 Million - $8.45 Million	-80,156 Reduced 32.98%	162,905 $16.6 Million
Q1 2023 May 15, 2023	SELL	$30.85 - $93.17 $15.1 Million - $45.7 Million	-490,671 Reduced 66.87%	243,061 $22.1 Million
Q4 2022 Feb 14, 2023	BUY	$22.15 - $42.11 $9.31 Million - $17.7 Million	420,490 Added 134.24%	733,732 $27.9 Million
Q3 2022 Nov 14, 2022	BUY	$19.41 - $36.49 $912,852 - $1.72 Million	47,030 Added 17.67%	313,242 $7.87 Million
Q2 2022 Oct 27, 2022	SELL	$20.71 - $36.5 $832,314 - $1.47 Million	-40,189 Reduced 13.12%	266,212 $8.09 Million
Q2 2022 Aug 15, 2022	SELL	$20.71 - $36.5 $832,314 - $1.47 Million	-40,189 Reduced 13.12%	266,212 $8.09 Million
Q1 2022 Oct 27, 2022	BUY	$24.12 - $39.6 $969,358 - $1.59 Million	40,189 Added 15.1%	306,401 $10 Million
Q1 2022 May 13, 2022	BUY	$24.12 - $39.6 $1.06 Million - $1.73 Million	43,804 Added 16.68%	306,401 $10 Million
Q4 2021 Feb 14, 2022	BUY	$25.61 - $110.96 $2.51 Million - $10.9 Million	98,122 Added 59.66%	262,597 $6.92 Million
Q3 2021 Nov 15, 2021	BUY	$100.0 - $143.02 $16.4 Million - $23.5 Million	164,475 New	164,475 $16.5 Million

62.7K

Ticker RETA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,583,200
Description
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.